Does RISANKIZUMAB-RZAA Cause Excessive granulation tissue? 6 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Excessive granulation tissue have been filed in association with RISANKIZUMAB-RZAA. This represents 0.0% of all adverse event reports for RISANKIZUMAB-RZAA.
6
Reports of Excessive granulation tissue with RISANKIZUMAB-RZAA
0.0%
of all RISANKIZUMAB-RZAA reports
0
Deaths
2
Hospitalizations
How Dangerous Is Excessive granulation tissue From RISANKIZUMAB-RZAA?
Of the 6 reports, 2 (33.3%) required hospitalization.
Is Excessive granulation tissue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Excessive granulation tissue?
CARBIDOPA\LEVODOPA (117)
ADALIMUMAB (38)
BACLOFEN (31)
ZOLEDRONIC ACID (29)
ZOMETA (27)
AREDIA (21)
METHOTREXATE (19)
RITUXIMAB (13)
BECAPLERMIN (11)
PAMIDRONATE (11)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Excessive granulation tissue Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA